文献速递主动脉疾病

急性与亚急性TEVAR对无并发症急性B型主动脉夹层远期结局的影响

Timing of endovascular repair impacts long-term outcomes of uncomplicated acute type B aortic dissection.
PubMed 文献 · J Vasc Surg · 2021-09-28

该回顾性研究纳入238例无并发症急性B型主动脉夹层患者,比较急性期与亚急性期TEVAR的5年结局。经逆概率加权后,两组全因死亡和主动脉相关死亡无显著差异,但急性期TEVAR在1年内复合不良事件发生率显著更高,提示亚急性期TEVAR可能更优。

要点

  • 急性与亚急性TEVAR的5年全因死亡和主动脉相关死亡无显著差异。
  • 急性期TEVAR在1年内复合不良事件风险显著高于亚急性期。
  • 无并发症急性B型主动脉夹层可考虑在亚急性期行TEVAR。

核心结论

  • 5年随访时,急性与亚急性TEVAR的全因死亡和主动脉相关死亡无显著差异。
  • 急性期TEVAR与1年内严重并发症发生率增加相关,提示亚急性期TEVAR可能更优。

研究设计与样本

  • 回顾性分析2008年3月至2018年9月238例接受急性或亚急性期TEVAR的无并发症急性B型主动脉夹层患者。
  • 采用逆概率治疗加权平衡基线特征,并进行加权Kaplan-Meier估计、界标分析和加权Cox模型。

主要发现

  • 加权后30天死亡率急性TEVAR组为1.5%,亚急性TEVAR组为0%(P = .24)。
  • 30天不良事件发生率急性TEVAR组为16.8%,亚急性TEVAR组为6.9%(P = .13)。
  • 5年全因死亡风险比1.50(95%CI 0.59-3.81,P = .39),主动脉相关死亡风险比1.11(95%CI 0.34-3.60,P = .86)。
  • 复合结局在急性TEVAR组发生30例(23.0%),亚急性TEVAR组18例(22.3%),风险比0.67(95%CI 0.36-1.25,P = .20)。
  • 界标分析显示治疗效应与时间存在显著交互作用(P交互 = .01),1年内复合结局风险比0.25(95%CI 0.08-0.79,P = .02),1至5年间风险比1.25(95%CI 0.56-2.76,P = .59)。

临床怎么用

  • 对于无并发症急性B型主动脉夹层,TEVAR时机选择需权衡1年内并发症风险,亚急性期可能更优。

局限性

  • 回顾性研究设计。
  • 单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the 5-year outcomes of acute versus subacute thoracic endovascular aortic repair (TEVAR) in patients with uncomplicated acute type B aortic dissection (ATBAD). METHODS: Between March 2008 and September 2018, 238 consecutive patients with uncomplicated ATBAD underwent TEVAR in the acute or subacute phase and were analyzed retrospectively. The primary end points were all-cause death and aortic-related death. The secondary end point was a composite of the outcomes of death from any cause, rupture, new dissection, retrograde type A aortic dissection, endoleak, and late reintervention. Inverse probability treatment weighting was used to balance baseline characteristics. Weight-adjusted Kaplan-Meier estimate with landmark analysis and weighted Cox model were performed to assess time-to-event outcomes. RESULTS: In the inverse probability treatment weighting-adjusted population, the 30-day mortality was 1.5% in the acute TEVAR group and 0% in the subacute TEVAR group (P = .24). The incidence of 30-day adverse events occurred in 16.8% and 6.9% patients in the acute TEVAR and subacute TEVAR groups, respectively (P = .13). At 5 years, there was no statistically significant difference in all-cause death (hazard ratio [HR], 1.50; 95% confidence interval [CI], 0.59-3.81; P = .39) and aortic-related death (HR, 1.11; 95% CI, 0.34-3.60; P = .86) between the two groups. The composite outcomes occurred in 30 patients (23.0%) in the acute TEVAR group and 18 patients (22.3%) in the subacute TEVAR group, respectively (HR, 0.67; 95% CI, 0.36-1.25; P = .20). However, a landmark analysis of the composite outcomes indicated that there was a significant interaction between treatment effect and time (Pinteraction = .01), with a significantly higher incidence of the composite outcomes in the acute TEVAR group compared with the subacute TEVAR group within 1 year (HR, 0.25; 95% CI, 0.08-0.79; P = .02), and a comparable rate between 1 and 5 years (HR, 1.25; 95% CI, 0.56-2.76; P = .59). CONCLUSIONS: At the 5-year follow-up, no significant differences exist in the all-cause death and aortic-related death between acute and subacute TEVAR. However, acute TEVAR is associated with an increased rate of severe complications within 1 year, which suggests that performing TEVAR in the subacute phase of ATBAD may be the preferable option.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Xiang D, Wu F, Chen L, et al. Timing of endovascular repair impacts long-term outcomes of uncomplicated acute type B aortic dissection. J Vasc Surg. 2021. PMID: 34592378. doi:10.1016/j.jvs.2021.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。